No history of any prior stroke (hemorrhagic or ischemic)
History of grade III hemorrhagic cystitis due to prior cyclophosphamide chemotherapy
History or evidence of thrombotic or hemorrhagic disorders within  months before first study treatment
TREATMENT EXCLUSION: Active hemorrhagic cystitis
Any history of hemorrhagic stroke
Major hemorrhagic event within  days
Patients with prior history of ventilator support related to lung injury such as pneumonia, hemorrhagic pneumonitis, capillary leakage are excluded
History of ventilator support related to lung injury (e.g., pneumonia, hemorrhagic pneumonitis, capillary leakage)
History of hemorrhagic or ischemic stroke within the last  months
History or evidence of thrombotic or hemorrhagic disorders within  months before first study treatment
Current thrombotic or hemorrhagic disorder/event or history of prior event within  months of start of screening
History of hemorrhagic CNS metastases
Subjects with active hemorrhagic diathesis
Known history of hereditary hemorrhagic telangiectasia (HHT).
MPD: Patients with polycythemia vera with persistent thrombotic or hemorrhagic complications despite conventional therapy, or who have progressed to postpolycythemic marrow fibrosis
History of thrombotic or hemorrhagic stroke or myocardial infarction within  months.
History of Osler-Weber-Rendu syndrome or hereditary hemorrhagic telangiectasia
Uncontrolled thromboembolic or hemorrhagic disorders.
History of congenital bleeding diathesesor anatomical anomaly that predisposes to hemorrhage (e.g. hemophilia, hereditary hemorrhagic telangiectasia).
Resolving hemorrhagic changes related to surgery.
Uncontrolled thrombotic or hemorrhagic disorder
Patients with hemorrhagic brain metastases
Patients with known allergy to etoposide or a history of grade  hemorrhagic cystitis with cyclophosphamide are not eligible
Patients with a history of thrombotic or hemorrhagic disorders
History of hemorrhagic or ischemic stroke within  months prior to first dose of mirvetuximab soravtansine
History or evidence of thrombotic or hemorrhagic disorders within  months prior to first dose of mirvetuximab soravtansine
Hemorrhagic, embolic, or thrombotic stroke within  months of scheduled dosing day ;
History of hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu syndrome)
Hereditary or chronic hemorrhagic or coagulopathy conditions (i.e., hemophilia)
Known bleeding diathesis Known history of hereditary hemorrhagic telangiectasia (HHT).
Patients with a history of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)
No history of hemorrhagic stroke
Documented hemorrhagic tendencies
Documented hemorrhagic tendencies (e.g., hemophilia)
History of bleeding disorder or hemorrhagic stroke
History of bleeding disorder or hemorrhagic stroke
Hemorrhagic cystitis or active prostatitis
Patient must not have hemorrhagic lesions
History of thrombotic or hemorrhagic stroke or myocardial infarction within  months
